Anup Sharma, PhD
Research Scientist of Surgery
Research & Publications
Biography
News
Research Summary
Epigenetics, Methylation Biomarkers, Early Cancer Detection, cell-free DNA approaches to monitor therapy response, Cancer Disparities, Pancreas Cancer Therapeutics
Extensive Research Description
My research focuses on a better understanding of epigenetic mechanisms pertaining to Pancreatic Cancer initiation and progression. I am also developing novel liquid biopsy-based technologies to analyze cell-free DNA in early cancer detection and to monitor therapeutic responses to chemotherapy.
I am also interested in the disparities in cancer outcomes with a special focus on the implications of racial diversity in the molecular landscape of pancreatic cancer.
Coauthors
Selected Publications
- Early Detection of Cancers in the Era of Precision OncologyTan W, Sharma A, Das P, Ahuja N. Early Detection of Cancers in the Era of Precision Oncology. Current Opinion In Oncology 2023, 35: 115-124. PMID: 36721896, DOI: 10.1097/cco.0000000000000931.
- Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasmsChhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.
- Use of distinct molecular signatures of appendiceal cancer subtypes to assess biomarker development.Tan W, Tian M, Ruzgar N, Hengartner A, Sailo B, Ang-Olson O, Ubas A, John N, Yaghoobi V, Tang H, Sharma A, Nalbantoglu I, Ahuja N. Use of distinct molecular signatures of appendiceal cancer subtypes to assess biomarker development. Journal Of Clinical Oncology 2023, 41: 189-189. DOI: 10.1200/jco.2023.41.4_suppl.189.
- A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrenceHeumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.
- Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control studyYaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O’Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study. Breast Cancer Research 2021, 23: 113. PMID: 34906209, PMCID: PMC8670126, DOI: 10.1186/s13058-021-01493-w.
- Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-AnalysisChhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2021, 162: 786-798. PMID: 34813861, DOI: 10.1053/j.gastro.2021.11.021.